@article{0fa4b9c9112a40ee89456181b79b90e5,
title = "Antimicrobial resistance in European isolates of Pseudomonas aeruginosa",
abstract = "Pseudomonas aeruginosa is responsible for a substantial fraction of hospital infections. Twenty-five European university hospitals submitted a total of 1411 Pseudomonas aeruginosa isolates for susceptibility testing during 1997 and 1998. The isolates showed highest susceptibility to amikacin (87.5%), meropenem (87.3%) and piperacillin/tazobactam (86.8%). Susceptibility to ciprofloxacin was 73.2%. There was no clear geographical distribution of resistance, although isolates from northwestern Europe tended to be more susceptible than those from southeastern Europe. Isolates that were resistant to one class of antibiotics were also often resistant to at least one other class of antibiotics. Imipenem-resistant isolates were generally not clonally related.",
author = "Fluit, {A. C.} and J. Verhoef and Schmitz, {F. J.} and H. Mittermayer and M. Struelens and F. Goldstein and V. Jarlier and J. Etienne and Courcol, {P. R.} and F. Daschner and U. Hadding and N. Legakis and Schito, {G. C.} and G. Raponi and P. Heczko and W. Hyrniewicz and D. Costa and E. Perea and F. Baquero and {Martin Alvarez}, R. and J. Bille and G. French and R. Andoni and V. Korten and S. Unal and D. G{\"u}r and N. Keller",
note = "Funding Information: Acknowledgements The SENTRY Antimicrobial Surveillance Program was funded by an educational grant from Bristol-Myers Squibb Pharmaceutical Company. The European Network for Antimicrobial Resistance and Epidemiology (ENARE) was funded by a grant (ERBCHRCT940554) from the European Union. The authors wish to thank M. Klootwijk, K. Kusters, A. Florijn, and S. de Vaal for exp ert technical assistance.",
year = "2000",
doi = "10.1007/s100960050497",
language = "אנגלית",
volume = "19",
pages = "370--374",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
number = "5",
}